An independent advisory panel of the FDA rejected MDMA-assisted therapy for PTSD citing concerns over study designs, participants guessing MDMA use, potential biases, and a case of misconduct in the study.
Panel expressed worries about the drug's cardiovascular effects, therapists' bias, and lack of detailed data on abuse potential of MDMA that generates bliss. Concerns raised on treatment benefits outweighing risks.
[
Collection
]
[
|
...
]